Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress

Reuters

2025/06/13

Enliven <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia $(CML.UK)$. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response $(MMR.AU)$ rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543688000"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543688000\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543688000?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543688000","market":"us","top_or_hot":-1,"title":"Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enliven <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia <a href=\"https://laohu8.com/S/CML.UK\">$(CML.UK)$</a>. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response <a href=\"https://laohu8.com/S/MMR.AU\">$(MMR.AU)$</a> rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-13 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enliven <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia <a href=\"https://laohu8.com/S/CML.UK\">$(CML.UK)$</a>. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response <a href=\"https://laohu8.com/S/MMR.AU\">$(MMR.AU)$</a> rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELVN","symbol_name":"Enliven Treateutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL9dn6BH:1","article_id":"2543688000","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543688000","pubTimestamp":1749809004,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia . The data was presented at the European Hematology Association  2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response  rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELVN":"Enliven Treateutics","BK4007":"制药"},"translate_title":"Enliven Therapeutics在EHA 2025大会上宣布ELVN-001治疗CML的积极1期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELVN":0.9},"content_text":"Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n    \n\n        Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia $(CML.UK)$. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response $(MMR.AU)$ rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}